SC
ADPT icon

SummitTX Capital’s Adaptive Biotechnologies ADPT Stock Holding History

SummitTX Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Sell
65,640
-251,984
-79% -$3.86M 0.04% 395
2026
Q1 		$4.41M Buy
+317,624
New +$5.06M 0.14% 173

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

SummitTX Capital's ADPT Position: Q2 2026 in Review

SummitTX Capital reduced its Adaptive Biotechnologies (ADPT) stake by 79% in Q2 2026, selling an estimated $3.86M and leaving 65,640 shares worth $1.41M. The position accounts for 0.04% of the portfolio, ranked #395.

SummitTX Capital first reported a position in ADPT in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.41M in Q1 2026. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • SummitTX Capital held 65,640 shares of Adaptive Biotechnologies worth $1.41M as of Q2 2026.
  • SummitTX Capital sold 251,984 Adaptive Biotechnologies shares in Q2 2026, an estimated $3.86M.
  • Adaptive Biotechnologies made up 0.04% of SummitTX Capital's portfolio in Q2 2026, its #395 holding.
  • SummitTX Capital first reported a position in Adaptive Biotechnologies in Q1 2026 and has held it in 2 quarters since.
  • SummitTX Capital's Adaptive Biotechnologies position peaked at $4.41M in Q1 2026.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.